| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.14 | 0.01 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.13 | 0.01 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.092 | 0.01 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.14 | 0.02 |
| mRNA | (5Z)-7-Oxozeaenol | GDSC1000 | pan-cancer | AAC | -0.09 | 0.02 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.02 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.15 | 0.02 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | -0.084 | 0.02 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | -0.085 | 0.02 |
| mRNA | AGK-2 | CTRPv2 | pan-cancer | AAC | 0.087 | 0.02 |